Even though this study was conducted in HIV-infected individuals, it also raises the possibility of exploiting the therapeutical potential of GHRH analogs in the treatment of NAFLD and NASH in other populations. The gene discussed is GHRH; the disease is metabolic dysfunction-associated steatotic liver disease.